Background. KLRG1 is a marker of terminally differentiated CD8 + T cells in viral infection, but its role in human Mycobacterium tuberculosis infection remains elusive.
Tuberculosis is one of the major causes of death due to infectious disease. Much effort has gone into developing vaccines against tuberculosis, but success has proven to be limited, highlighting our incomplete understanding of immunity against this disease. CD4 + T cells are critical for resistance to Mycobacterium tuberculosis infection [1] , but how effective T-cell responses are maintained during chronic infection is not well understood.
The expression of killer cell lectin-like receptor G1 (KLRG1) in antigen-experienced T cells has been found in both mice and humans [2, 3] . Several acute viral and bacterial infection models showed that KLRG1 could be used as a marker to define shortlived effector CD8 + T cells [4] [5] [6] . KLRG1 possesses an immune receptor tyrosine-based inhibitory motif, suggesting that it also plays a functional role in the immune system [7] .
In murine tuberculosis models, KLRG1-expressing CD4 + T cells had a short life-span and heightened capacity to produce cytokines, whereas KLRG1 -PD1 + CD4 + T cells were highly proliferative and could further differentiate into KLRG1 + cells [8] . Klrg1 −/− mice survived significantly longer after M. tuberculosis infection, which was associated with an increased number of T cells capable of secreting cytokines [9] . After infection, M. tuberculosis-specific CD4 + T cells present in the lung parenchyma exhibited a KLRG1 -CXCR3 + phenotype and conferred better protection, compared with their counterparts, KLRG1 + CX3CR1 + CD4 + T cells, which were retained in the blood vasculature and provided limited protection [10, 11] . Mice with interleukin 27 receptor-deficient T cells had reduced KLRG1 expression but greater protection against chronic M. tuberculosis infection, which was associated with accumulation of T cells in the lung parenchyma [12] . Moreover, KLRG1 expression on lung T cells kept dropping during anti-M. tuberculosis chemotherapy in mice [13] . These data suggested that the antigen-driven expression of KLRG1 in CD4 + T cells might be detrimental to the anti-M. tuberculosis immune responses.
Vaccine-induced antigen-specific KLRG1 -CD4 + T cells were reported to be central-memory-like T cells with pronounced proliferative ability and with the potential to continuously replenish the T cells at the site of infection [14, 15] . We and others also found that vaccine-induced antigen-specific lung-resident CD4 + T cells were KLRG1 negative but CXCR3 positive [16, 17] . Loss of BCG vaccine-induced protection correlated with an increase of KLRG1-expressing T cells [18] . These data suggested that KLRG1 expression on vaccine-induced antigen-specific CD4 + T cells might inversely correlate with the expression of immune protection. However, the role of KLRG1 in human tuberculosis still remains elusive. In this study, we delineated the profile of KLRG1 + CD4 + T cells in patients with tuberculosis and indicated a functional role of KLRG1 in human anti-M. tuberculosis immunity.
MATERIAL AND METHODS

Subjects
This study was approved by the Ethical Committee of Shanghai Public Health Clinical Center, and informed consent was obtained from all subjects. The first cohort comprised 45 patients with active tuberculosis, 52 healthy volunteers, and 23 patients without tuberculosis with other lung diseases and was used to determine the expression profile of KLRG1. Another 260 patients with active tuberculosis were randomly divided into 12 cohorts in different experiments to characterize the role of KLRG1 in tuberculosis (Supplementary Figure 1 and Table 1 ). Active tuberculosis was identified on the basis of sputum or effusion smear positivity and/or culture positivity and was further confirmed by radiological findings, clinical syndromes, polymerase chain reaction (PCR) amplification, and treatment responses in patients who had received anti-M. tuberculosis therapy for <2 months; PCR amplification of the M. tuberculosis complex-specific gene IS6110 was used to exclude nontuberculosis mycobacteria infection from smear/culture-positive cases (MeltPro, Zeesan Biotech, Xiamen). Healthy volunteers were T-SPOT.TB negative and without clinical signs of disease. Patients without tuberculosis were patients with other lung diseases, such as lung cancer, pneumonia, chronic bronchitis, and bronchiectasis, and were negative for M. tuberculosis on sputum smear or culture. All subjects had received BCG vaccine at birth, were HIV/HCV negative and were not taking immunosuppressive drugs.
Peripheral Blood Mononuclear Cell (PBMC) Isolation
PBMCs were isolated from freshly heparinized blood by Ficoll density centrifugation. The isolated cells were randomly allocated and immediately subjected to stimulation and analysis.
Intracellular Cytokine Staining
For intracellular cytokine detection, PBMCs were stimulated with 10 µg/mL purified protein derivative (PPD; Statens Serum Institute, Denmark) in the presence of monensin and brefeldin A (BD Biosciences, San Jose, CA) for 12 hours in Roswell Park Memorial Institute 1640 medium containing 10% fetal bovine serum and 100 mg/mL penicillin-streptomycin. PBMCs cultured in the medium were used as negative controls. PMA (50 ng/mL, Sigma, Germany) plus ionomycin (1 µg/mL, Sigma) was used to stimulate cytokine secretion as a positive control; CD3 plus CD28 (both 1 µg/mL; eBioscience, San Diego, CA) was used as a positive control to stimulate pAkt signal. After stimulation, cells were washed and incubated on ice with a mixture of antibodies against surface markers for 30 minutes, followed by washing, fixation, and permeabilization with fix/perm buffers (BD Biosciences). The fixed cells were then treated with antibodies against intracellular cytokines and incubated for another 30 minutes on ice, and the cells were then washed and analyzed by flow cytometry with the LSRFortessa system (BD Biosciences) and FlowJo software (Ashland, OR).
FoxP3 and Ki-67 Staining
The cells were stained with surface antibodies as indicated above, washed, and subject to the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Briefly, the cells were incubated with Foxp3 fixation/permeabilization working solution in the dark at room temperature for 60 minutes. After washing with permeabilization buffer, the cells were incubated with fluorochrome-conjugated Foxp3 antibody in the dark at room temperature for another 60 minutes and then were washed and analyzed by flow cytometry.
Apoptosis Analysis
PBMCs were cultured in the medium or stimulated with PPD (10 µg/mL) and/or ESAT-6 and CFP10 peptide pools (10 µg/ mL each) and subjected to surface staining. After staining with 5 µL of annexin V-FITC and 5 µL of propidium iodide (PI) (Dojindo Laboratories, Japan) for 15 minutes at room temperature, the cells were then washed and analyzed by flow cytometry within 1 h.
Antibodies
Information about antibodies is available in the Supplementary Materials.
KLRG1 Blockage
The blockage of KLRG1 was performed as illustrated elsewhere [19] . Briefly, PBMCs from patients with active tuberculosis were incubated with anti-human KLRG1 antibody (clone 14C2A07) or isotype-control IgG antibody (both 4 µg/mL; Biolegend, San Diego, CA) in the presence of stimulators and then analyzed as indicated in the figure legends.
Inhibition of Akt
The inhibition of Akt was performed as described elsewhere [20] . Briefly, PBMCs were incubated with PPD with or without anti-KLRG1 antibody treatment in the presence of the Akt inhibitor 1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate at a final concentration of 5 µM (Calbiochem, San Diego, CA).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6 software (La Jolla, CA). The statistical differences between 2 groups were assessed using unpaired or paired t tests, as indicated in the figure legends. For multiple-group comparisons, 1-way analysis of variance was used.
RESULTS
KLRG1 Is Overexpressed on CD4 + T Cells in Patients With
Tuberculosis
To explore the role of KLRG1 in human anti-M. tuberculosis immunity, the expression of KLRG1 on T cells was determined in our cohort (the gating strategy is shown in Supplementary  Figure 2 ). As shown in Figure 1A and 1B, the percentage of KLRG1 + cells among CD4 + T cells was significantly higher in patients with tuberculosis, compared with healthy controls or patients without tuberculosis, particularly after stimulation with PPD of M. tuberculosis. In contrast, expression of KLRG1 on CD4 + cells was comparable between patients without tuberculosis and healthy controls. However, the frequency of KLRG1 + among CD8 + T cells was similar in patients with active tuberculosis and healthy controls ( Figure 1C and 1D) . Interestingly, the percentage of KLRG1 + cells among CD8 + T cells was significantly higher in patients without tuberculosis, suggesting that KLRG1 + on terminally differentiated CD8 + T cells was upregulated by other lung diseases. Additionally, the bronchoalveolar lavage (BAL) fluid-derived cells also expressed KLRG1; however, there was no significant difference between BAL fluid-derived cells and PBMCs from patients with tuberculosis (Supplementary Figure 3A) , and KLRG1 expression was affected in all tuberculosis cases regardless of smear or culture results (Supplementary Figure 3B) . Thus, these results suggested that tuberculosis might induce terminal T-cell differentiation associated with KLRG1 expression on CD4 + T cells instead of on CD8 + T cells.
Profiles of Surface Marker Expression on KLRG1 + CD4 + T Cells
To investigate the KLRG1 coexpression patterns in patients with tuberculosis, KLRG1-bearing CD4 + T cells were costained with appropriate T-cell activation markers. As shown in Supplementary Figure 4 , the vast majority of KLRG1 + CD4 + T cells were CD45RA -, indicative of nonmemory cells. Moreover, KLRG1 + CD4 + T cells expressed significantly higher levels of PD1, which promotes apoptosis in human T cells, compared with KLRG1 -CD4 + T cells (Supplementary Figure 4) . Additionally, a higher expression of CCR7 and a reduced expression of CD154 was found in KLRG1-expressing CD4 + T cells. However, the expression of CD38, CD69, or CD127 was not associated with KLRG1 expression in our cohort (Supplementary Figure 4) . Taken together, these results support the view that the majority of KLRG1 + CD4 + T cells belong to the effector T-cell pool and have a unique receptor expression pattern.
KLRG1 + CD4 + T Cells Express Higher Levels of Intracellular
Cytokines in Patients With Tuberculosis
When we compared the cytokine content in KLRG1 + and KLRG1 -CD4 + T cells after PPD ex vivo stimulation, the levels of IFN-γ, IL-2, and TNF-α ( Figure 2A ) were significantly higher in KLRG1 + CD4 + T cells (the gating strategy is shown in Supplementary Figure 5A ). The differences reached statistical significance in the triple-positive cells, all double-positive cells, and IL-2 or TNF-α single-positive cells ( Figure 2B ). In addition, the level of KLRG1 expression in PPD-responding CD4 + T cells (the cells expressing at least 1 cytokine) was approximately 3.5 times higher than that in nonresponding cells ( Figure 2C ). Thus, the KLRG1 + CD4 + T cells had a greater ability to produce cytokines than their KLRG1-negative counterparts in patients with active tuberculosis. CFU, colony-forming units; NS, not significant. *P < .05, **P < .01, and *** P < .001, by 1-way analysis of variance, for comparisons between 2 groups.
Enhanced Cytokine Production in KLRG1-Expressing CD4 + T Cells Is Associated With a Decreased Proportion of Tregs and Increased Akt Signaling
It was reported elsewhere that the frequency of Tregs was inversely correlated with M. tuberculosis-specific immunity [21] .
We asked whether the enhanced cytokine secretion ability of the KLRG1 + CD4 + T cells was associated with the frequency of Tregs (the gating controls of CD25 and FoxP3 staining are shown in Supplementary Figure 5B ). Our data showed that the percentage of Tregs was significantly lower in the KLRG1 + CD4 + T subsets in patients with active tuberculosis, no matter whether stimulated with PPD or ESAT-6/CFP10 peptides or unstimulated ( Figure 3A and 3B).
Considering phosphorylation of Akt and expression of PTEN, a negative regulator of Akt signaling [23] . Representative histograms are shown in Supplementary Figure 6A . The percentage of cells stained, median fluorescence intensity (MFI) and integrated MFI (iMFI) values of phosphorylated Akt (pAkt) were all significantly higher in KLRG1 + CD4 + T cells compared with their KLRG1 -counterparts after PPD stimulation ( Figure 3C) . Additionally, the expression of PTEN, the negative regulatory molecule, was significantly depressed in KLRG1 + CD4 + T-cell subsets ( Figure 3D ). In contrast, the differences did not reach significance after CD3 and CD28 nonspecific stimulation (Supplementary Figure 6B and 6C) . Thus, these data suggested that decreased Treg distribution and enhanced Akt signaling may be implicated in the increased effector function of the terminally differentiated KLRG1 + CD4 + T cells in patients with active tuberculosis.
Impaired Expansion Ability of the KLRG1 + CD4 + T-Cell Population Is Indicated by a High Apoptosis Rate
Since KLRG1 + CD4 + T cells have an impaired ability to proliferate in M. tuberculosis-infected mice [8] , we asked whether the KLRG1 + CD4 + T cells in patients with active tuberculosis also had a different ability to survive. The percentage of KLRG1-expressing CD4 + T cells was evaluated at days 1, 3, and 6 after ex vivo stimulation with PPD or ESAT-6/CFP10 or no stimulation. As shown in Figure 4A and 4B, the percentage of KLRG1 + CD4 + cells kept dropping over time, even after stimulation with PPD ( Figure 4B ) or ESAT-6/CFP10 (Supplementary Figure 7A) , suggesting that these terminally differentiated CD4 + T cells had a short life-span during chronic tuberculosis. As a control, the frequency of CD127-expressing CD4 + T cells was relatively constant during in vitro culture (Supplementary Figure 7B) . Next, we compared the apoptosis rate and proliferation ability between KLRG1 + CD4 + and KLRG1 -CD4 + T cells. Representative dot plots and summary data of apoptosis are shown in Figure 4C (the staining controls are shown in Supplementary Figure 7C) . The apoptosis rate was significantly higher in KLRG1 + CD4 + T cells, compared with KLRG1 -counterparts after PPD ( Figure 4C ) or ESAT-6/CFP10 stimulation or even no stimulation (Supplementary Figure 7D) . In contrast, the expression of Ki-67, a marker of proliferative cells, was found to be similar between these 2 subsets ( Figure 4D ). Although stimulation with PPD and ESAT-6/CFP10 increased Ki-67's expression (the gating strategy of Ki-67 is shown in Supplementary  Figure 8A ), no significant differences were observed between these 2 subsets even after M. tuberculosis antigen exposure ( Figure 4D and Supplementary Figure 8B) . Together, these data show that the capacity of the KLRG1 + CD4 + T-cell population in patients with tuberculosis to expand was probably impaired in association with a high apoptosis rate but an unchanged proliferation ability.
Blockage of KLRG1 Increases the Production of AntigenSpecific Cytokines by CD4 + T Cells
The association of KLRG1 positivity with an increased effector function and apoptosis indicated a possible role of KLRG1 as a membrane signal transducer. We therefore asked whether ex vivo blockage of KLRG1 by a specific antibody might influence the function of CD4 + T cells in our cohort ( Figure 5A ). The addition of KLRG1 blocking antibody did not affected the cell viability of magnet-sorted KLRG1 + CD4 + T cells (Supplementary Figure 9) . Unexpectedly, the blockage of KLRG1 had no obvious impact on either the proliferation ability or the apoptosis rate of the CD4 + T cells (Figure 5B ), compared with the control treatment with isotype-matched nonspecific antibody. However, the inhibition of KLRG1 significantly enhanced the production of IFN-γ and IL-2 after PPD stimulation, whereas TNF-α was not significantly influenced ( Figure 5C ). These data suggested that manipulating this inhibitory receptor might boost the anti-M. tuberculosis CD4 + T-cell immune responses. The enhanced production of cytokines induced by KLRG1 blockage was not detectable in the presence of PMA and ionomycin as potent nonspecific stimulators ( Figure 5D ), suggesting that the effect of KLRG1 blockage on cytokine secretion was M. tuberculosis specific in patients with active tuberculosis.
Increased Cytokine Secretion Induced by KLRG1 Blockage Is Mediated by an Akt Signaling Pathway
In the presence of anti-KLRG1 antibody, the KLRG1 + CD4 + cells had significantly increased levels of pAkt, compared with isotype control (Figure 6A ), suggesting that the enhanced cytokine secretion induced by KLRG1 blockage was mediated by Akt signaling. In the presence of a cell-permeable Akt inhibitor, 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, KLRG1 blockage did not enhance CD4 + T-cell responses ( Figure 6B ), thus confirming the involvement of Akt in the increased cytokine secretion.
DISCUSSION
Increasing data have suggested that KLRG1 could be used as a marker of effector CD4 + T cells during murine tuberculosis [8] [9] [10] [11] [12] . However, the role of KLRG1 in human tuberculosis has not been clarified. Herein, we demonstrated that CD4 + T cells from patients with active tuberculosis overexpressed KLRG1, whereas CD8 + T cells did not (Figure 1) . Further, we showed that KLRG1 + CD4 + T cells expressed significantly higher levels of cytokines after ex vivo M. tuberculosis-specific stimulation. compared with KLRG1 -CD4 + T cells (Figure 2 ), confirming the expected terminally differentiated status of KLRG1 + CD4 + T-cell effectors in human tuberculosis.
Although a recent study reported only slight, insignificant increase of KLRG1 expression on CD4 + T cells in patients with active tuberculosis [24] , this contrast with our findings might be due to the small sample size used in that study. Moreover, no KLRG1 was found expressed on T cells unless they were BCG stimulated, bringing into question the methods used there, since KLRG1 is usually highly expressed on CD4 + T cells at background level (range, approximately 8% to 28% of cells) [3, 25] . Considering that the protective immune response against tuberculosis is mainly induced by Th1 CD4 + T cells, the significantly increased expression of KLRG1 on CD4 + T cells that we observed suggested that KLRG1 + effectors that were upregulated by the immune system would help resist the infection. Accordingly, we investigated their properties and functions during M. tuberculosis infection. We found that the percentage of KLRG1 + CD4 + T cells progressively decreased during ex vivo cell maintenance, whether or not the cells were stimulated with antigen ( Figure 4B ). This suggested that terminally differentiated KLRG1-expressing CD4 + T cells have a survival defect after M. tuberculosis exposure. Hence, to maintain the anti-M. tuberculosis activities, a sustained differentiation from memory T cells into the KLRG1 + effectors would be needed during chronic tuberculosis. In adoptive transferred mice models, the purified PD1 + KLRG1 -CD4 + T cells could be differentiated into in KLRG1-expressing effectors through cell division. However, PD-1 and KLRG1 were highly coexpressed in our cohort (Supplementary Figure 4) . This suggests that the maintenance of KLRG1 cells during M. tuberculosis infection may require the sustained differentiation from other cell subsets, not only from PD-1-expressing cells in human.
Although in a M. tuberculosis-infected mouse model the KLRG1-expressing antigen-specific CD4 + T cells exhibited an impaired proliferation ability [8] , here we found no significant difference in Ki-67 expression ( Figure 4D ). However, we found that the apoptosis rate was significantly higher in KLRG1 + CD4 + T cells (Figure 4C ), consistent with the impaired survival ability of this cell subset ( Figure 4B ). The association of KLRG1 with apoptosis provided strong evidence that KLRG1 can be regarded as a marker of terminal differentiation in human tuberculosis.
A recent study in mice showed that antigen-specific KLRG1 + CD4 + T cells were located in lung vasculature, whereas KLRG1 -CXCR3 + CD4 + T cells accumulated in the parenchyma during M. tuberculosis infection [10] . This restricted location . P values were determined by the paired t test. B, Enhanced cytokine secretion induced by KLRG1 blockade was prevented by Akt inhibitor. The production of interferon γ (IFN-γ), interleukin 2 (IL-2), and tumor necrosis factor α (TNF-α) among CD4 + T cells after purified protein derivative stimulation in the presence of antibody against KLRG1 with or without Akt inhibitor is shown. Each symbol triplet represents an individual subject (n = 22). NS, not significant. **P < .01 and ***P < .001, by the paired t test, for comparisons between 2 groups.
was consistent with evidence that tissue-resident memory CD8 + T cells from various organs such as skin [26] , small intestine [27] , and salivary glands [28] do not express KLRG1. Thus, KLRG1 and its counterpart, CXCR3, could be used as markers of terminally differentiated lung-stroma-resident CD4 + T cells in anti-M. tuberculosis immune responses. We previously reported that a novel Sendai virus-vectored vaccine could induce lung-parenchyma-located CXCR3 + KLRG1 -memory CD4 + T cells in mice [17] . However, the immune protection induced by this vaccine was mainly mediated by lung-resident CD103 + CD8 + T cells [17] . Interestingly, despite binding to the same E-cadherin ligand, CD103 and KLRG1 influence the interaction of T cells in an opposite manner [29] . In contrast to KLRG1, CD103 has been widely used as a marker of tissue resident CD8 + T cells [30] . Taken together, these findings suggest that an increase of KLRG1 on CD4 + T cells that are encountering antigen diffusing from sites of infection might actually have a detrimental effect on expression of M. tuberculosis immunity by enhancing stromal adherence and impairing access of the terminal effector cells to the lung parenchyma.
Although KLRG1 + CD4 + T cells produced high levels of intracellular cytokines, in a KLRG1-knockout mouse both cytokine production and resistance against M. tuberculosis infection were increased [9] , suggesting that KLRG1 may have a negative impact on protective immunity. Indeed, recent studies have indicated that KLRG1 may play a functional role as an inhibitory receptor in the immune system. KLRG1 can inhibit a suboptimal positive T-cell receptor signal [31] through decreasing Ca 2+ influx [32] and inhibit CD95L-mediated lysis and NFAT activation [33] , leading to the inhibition of antigen-induced cell division and cytolytic activity of CD8 + T cells [34] . Consistent with these inhibitory effects, blocking KLRG1 signaling during T-cell receptor activation led to a significant enhancement of Akt phosphorylation and proliferative activity of CD8 + T cells [20] .
Cumulatively, these studies have provided strong evidence that KLRG1 expression on T cells can impact the immune responses; accordingly, it is possible that modulating this molecular marker of highly differentiated cells could boost immunotherapeutic regimes. We showed here that treatment with anti-KLRG1 antibody significantly increased cytokine expression without impairing cell survival ability ( Figure 5 ), indicating that targeting KLRG1 on CD4 + T cells might enhance anti-M. tuberculosis immune responses. Moreover, our evidence further showed that the enhanced cytokine expression was mediated by an Akt signaling pathway (Figure 6 ), a key regulator of various physiological functions [35] . Recently, we also found that a vaccinia virus-vectored vaccine shaped the T-cell functional avidity maturation through the MyD88-Akt-PTEN pathway [36, 37] . Cumulatively, our studies suggest that the Akt pathway might be a promising therapeutic target against tuberculosis.
Taken together, our observations delineated the profile and functional roles of KLRG1-expressing CD4 + T cells in patients with tuberculosis. Although the findings in the mouse study were confirmed in this human cohort study, differences in the KLRG1-expressing CD4 + T cells during tuberculosis in these 2 models still could be seen and are summarized in Supplementary Figure 10 . Nevertheless, the evidence is consistent with the view that the inadequacy of T-cell responses during chronic M. tuberculosis infection may be, at least in part, a consequence of CD4 + T cells being driven to a less protective terminally differentiated state marked by KLRG1 expression [10, 38] . Although in active tuberculosis these KLRG1-expressing CD4 + T cells are present in greater numbers in the blood circulation, stromal adherence may restrict their access to sites of infection. Furthermore, their increased apoptosis rate after M. tuberculosis exposure and/or under antigen stimulation implies a sustained differentiation from KLRG1 -memory CD4 + T cells, which might in itself impair the balance of T-cell immunity by draining the pool of undifferentiated cells. Because blocking the KLRG1 pathway enhanced the production of intracellular cytokines via Akt signaling without interfering with cell survival ability, we suggest that the KLRG1/Akt signaling pathway provides a potential target for development of anti-M. tuberculosis immunotherapeutic regimens.
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